Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

<p>SMG8/9 mutation does not reverse the inhibition of ATR/CHK1 signaling but abrogates ATRi-associated cell-cycle effects, RFS, and TRCs. <b>A,</b> SMG8 and SMG9 mutant cells do not show increased pCHK1 (Ser317 and Ser345) or total CHK1 protein expression levels compared with the W...

保存先:

書誌詳細
第一著者:	Marta J. Llorca-Cardenosa (14961612) (author)
その他の著者:	Lauren I. Aronson (14961615) (author), Dragomir B. Krastev (14961618) (author), Jadwiga Nieminuszczy (14961621) (author), John Alexander (14961624) (author), Feifei Song (14961627) (author), Malgorzata Dylewska (14961630) (author), Ronan Broderick (14961633) (author), Rachel Brough (14961636) (author), Astrid Zimmermann (14961639) (author), Frank T. Zenke (14961642) (author), Bora Gurel (14961645) (author), Ruth Riisnaes (14961648) (author), Ana Ferreira (14961651) (author), Theodoros Roumeliotis (14961654) (author), Jyoti Choudhary (14961657) (author), Stephen J. Pettitt (14952601) (author), Johann de Bono (14961660) (author), Andres Cervantes (14961663) (author), Syed Haider (14961666) (author), Wojciech Niedzwiedz (14961669) (author), Christopher J. Lord (14952616) (author), Irene Y. Chong (14961672) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development DNA Damage and Repair DNA repair Drug Mechanisms Drug Resistance Gastrointestinal Cancers Stomach cancer
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
著者:: Marta J. Llorca-Cardenosa (14961612)
出版事項: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
著者:: Marta J. Llorca-Cardenosa (14961612)
出版事項: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
著者:: Marta J. Llorca-Cardenosa (14961612)
出版事項: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
著者:: Marta J. Llorca-Cardenosa (14961612)
出版事項: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
著者:: Kavya Ramkumar (16474203)
出版事項: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
著者:: Min Wei (16918572)
出版事項: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
著者:: Min Wei (16918572)
出版事項: (2025)

Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
著者:: Biagio Ricciuti (14951247)
出版事項: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
著者:: Chuandong Geng (17315310)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_549kcpdi6l90nnrnpuorgr1g0q